We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Circulating Tumor DNA Associated with Triple-Negative Breast Cancer Recurrence

By LabMedica International staff writers
Posted on 27 Jul 2020
Patients with early-stage triple-negative breast cancer (TNBC) are frequently treated with neoadjuvant chemotherapy, based on the increased risk for recurrence and death associated with this category of tumors.

A subset of these patients continue to live without recurrence but a significant number still see their disease return despite this added chemotherapy. More...
Blood-based genomic testing, or liquid biopsy, has rapidly become popular for patients with TNBC and other cancers to identify those who may have residual cancer present and whose outcome might be improved with new or existing treatments.

A team of medial scientist from different universities and led by those at Indiana University Cancer Center (Indianapolis, IN, USA) conducted a study using data from 196 female patients in BRE12-158, a phase 2 multicenter randomized clinical trial that randomized patients with early-stage TNBC who had residual disease after neoadjuvant chemotherapy to receive post-neoadjuvant genomically directed therapy versus treatment of physician choice.

Patients had blood samples collected for circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) at time of treatment assignment; ctDNA analysis with survival was performed for 142 patients, and CTC analysis with survival was performed for 123 patients. Median clinical follow-up was 17.2 months (range, 0.3-58.3 months). ctDNA was sequenced using the FoundationACT or FoundationOneLiquid Assay (Foundation Medicine, Cambridge, MA, USA), and CTCs were enumerated using an epithelial cell adhesion molecule–based (EpCAM), positive-selection microfluidic device.

The scientists reported that for the 112 patients for whom both ctDNA and CTC results were available, there was no significant association between CTC positivity and ctDNA positivity. In other words, some patients were positive for one marker and not the other. As a result, the sensitivity to detect recurrences across the cohort was highest when both markers were considered: MRD sensitivity was 79% with ctDNA alone, 62% with CTCs alone, and 90% when combined.

Patients who were both ctDNA positive and CTC positive had significantly inferior distant disease-free survival (DFS) when compared with those who were double-negative. At 24 months, distant DFS probability was 52% for patients who were positive for both biomarkers compared with 89% for those who were negative. Similar trends were observed for non-distant DFS and for overall survival. The study was published on July 9, 2020 in the journal JAMA Oncology.

Related Links:
Indiana University Cancer Center
Foundation Medicine



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.